Rapid and sensitive detection of KRAS mutation after fast-COLD-PCR enrichment and high-resolution melting analysis

Diagnostic Molecular Pathology

Volumn 20, Issue 2, 2011, Pages 81-89

  Song, Chen ^a,b   Milbury, Coren A ^a   Li, Jin ^a   Liu, Pingfang ^a   Zhao, Meiping ^b   Makrigiorgos, Gerasimos Mike ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b PEKING UNIVERSITY   (China)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

COLD PCR; HRM; KRAS; lung adenocarcinoma; mutation detection

Indexed keywords

DNA; K RAS PROTEIN;

ARTICLE; CANCER DIAGNOSIS; CODON; CONTROLLED STUDY; FAST COAMPLIFICATION AT LOWER DENATURATION TEMPERATURE POLYMERASE CHAIN REACTION; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN CELL; LIMIT OF DETECTION; LUNG ADENOCARCINOMA; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

ADENOCARCINOMA; HUMANS; LUNG NEOPLASMS; PATHOLOGY, MOLECULAR; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SENSITIVITY AND SPECIFICITY; TRANSITION TEMPERATURE;

EID: 79958062775     PISSN: 10529551     EISSN: 15334066     Source Type: Journal    
DOI: 10.1097/PDM.0b013e3181fde92f     Document Type: Article

References (44)

1. Han SW, Kim TY, Jeon YK, et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res. 2006;12:2538-2544.
2. Samowitz WS, Curtin K, Schaffer D, et al. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev. 2000;9:1193-1197.
3. Wilentz RE, Chung CH, Sturm PD, et al. K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. Cancer. 1998;82:96-103. (Pubitemid 28070484)
4. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992-3995.
5. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007;67:2643-2648. (Pubitemid 46548951)
6. Shah SP, Morin RD, Khattra J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature. 2009;461:809-813.
7. Kalikaki A, Koutsopoulos A, Trypaki M, et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer. 2008;99:923-929.
8. Cortot AB, Italiano A, Burel-Vandenbos F, et al. KRAS mutation status in primary nonsmall cell lung cancer and matched metastases. Cancer. 2010;116:2682-2687.
9. Burmer GC, Loeb LA. Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma. Proc Natl Acad Sci U S A. 1989;86:2403-2407. (Pubitemid 19102517)
10. Behn M, Qun S, Pankow W, et al. Frequent detection of ras and p53 mutations in brush cytology samples from lung cancer patients by a restriction fragment length polymorphism-based "enriched PCR" technique. Clin Cancer Res. 1998;4:361-371. (Pubitemid 28122751)
11. Jenkins GJS, Hashemzadeh Chaleshtori M, Song H, et al. Mutation analysis using the restriction site mutation (RSM) assay. Mutat Res/ Fundam Mol Mech Mutagen. 1998;405:209-220. (Pubitemid 29042197)
12. Bielas JH, Loeb KR, Rubin BP, et al. Human cancers express a mutator phenotype. Proc Natl Acad Sci U S A. 2006;103:18238-18242. (Pubitemid 44871642)
13. Thomas RK, Nickerson E, Simons JF, et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med. 2006;12:852-855. (Pubitemid 44050078)
14. Sachidanandam R, Weissman D, Schmidt SC, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001;409:928-933. (Pubitemid 32165347)
15. Sakurada A, Lara-Guerra H, Liu N, et al. Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. J Thorac Oncol. 2008;3: 527-529. (Pubitemid 351630282)
16. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040-2048. (Pubitemid 350106711)
17. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn. 2005;7:413-421. (Pubitemid 41149657)
18. Li J, Wang L, Mamon H, et al. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med. 2008;14:579-584. (Pubitemid 351655208)
19. Li J, Milbury CA, Li C, et al. Two-round coamplification at lower denaturation temperature-PCR (COLD-PCR)-based sanger sequencing identifies a novel spectrum of low-level mutations in lung adenocarcinoma. Hum Mutat. 2009;30:1583-1590.
20. Milbury CA, Li J, Makrigiorgos GM. COLD-PCR-enhanced highresolution melting enables rapid and selective identification of lowlevel unknown mutations. Clin Chem. 2009;55:2130-2143.
21. Li J, Makrigiorgos GM. COLD-PCR: a new platform for highly improved mutation detection in cancer and genetic testing. Biochem Soc Trans. 2009;37:427-432.
22. Milbury CA, Li J, Makrigiorgos GM. PCR-based methods for the enrichment of minority alleles and mutations. Clin Chem. 2009;55: 632-640.
23. Gundry CN, Vandersteen JG, Reed GH, et al. Amplicon melting analysis with labeled primers: a closed-tube method for differentiating homozygotes and heterozygotes. Clin Chem. 2003;49:396-406. (Pubitemid 36250200)
24. Erali M, Voelkerding KV, Wittwer CT. High resolution melting applications for clinical laboratory medicine. Exp Mol Pathol. 2008;85:50-58.
25. Krypuy M, Newnham GM, Thomas DM, et al. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer. 2006;6:e295.
26. Do H, KrypuyM, Mitchell PL, et al. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer. 2008;8:142.
27. Ma ES, Wong CL, Law FB, et al. Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis. J Clin Pathol. 2009;62:886-891.
28. Do H, Dobrovic A. Limited copy number-high resolution melting (LCN-HRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies. Mol Cancer. 2009;8:82.
29. Amicarelli G, Adlerstein D, Shehi E, et al. Genotype-specific signal generation based on digestion of 3-way DNA junctions: application to KRAS variation detection. Clin Chem. 2006;52:1855-1863. (Pubitemid 44470692)
30. Binladen J, Thomas M, Gilbert P, et al. 50-Tailed sequencing primers improve sequencing quality of PCR products. BioTechniques. 2007;42:174-176.
31. McGrath JP, Capon DJ, Smith DH, et al. Structure and organization of the human ki-ras proto-oncogene and a related processed pseudogene. Nature. 1983;304:501-506. (Pubitemid 13026945)
32. Araki T, Shimizu K, Nakamura K, et al. Usefulness of peptide nucleic acid (PNA)-clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon 12 mutations in lung adenocarcinoma: comparison of PNA-clamp SmartAmp2 and PCR-related methods. J Mol Diagn. 2010;12:118-124.
33. Amicarelli G, Shehi E, Makrigiorgos GM, et al. FLAG assay as a novel method for real-time signal generation during PCR: application to detection and genotyping of KRAS codon 12 mutations. Nucleic Acids Res. 2007;35:e131.
34. Clayton SJ, Scott FM, Walker J, et al. K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification. Clin Chem. 2000;46:1929-1938.
35. Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci U S A. 2003;100:776-781. (Pubitemid 36183906)
36. Fan HC, Blumenfeld YJ, Chitkara U, et al. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci U S A. 2008;105:16266-16271.
37. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61:1659-1665. (Pubitemid 34292602)
38. Pujol JL, Simony J, Laurent JC, et al. Phenotypic heterogeneity studied by immunohistochemistry and aneuploidy in non-small cell lung cancers. Cancer Res. 1989;49:2797-2802. (Pubitemid 19143418)
39. Losi L, Baisse B, Bouzourene H, et al. Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis. 2005;26:916-922. (Pubitemid 41214320)
40. Wang X, Wang M, MacLennan GT, et al. Evidence for common clonal origin of multifocal lung cancers. J Natl Cancer Inst. 2009; 101:560-570.
41. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007;446:153-158. (Pubitemid 46398669)
42. Weichert W, Schewe C, Lehmann A, et al. KRAS genotyping of paraffinembedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn. 2010;12:35-42.
43. Bamford S, Dawson E, Forbes S, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 2004;91:355-358. (Pubitemid 39037083)
44. Zuo Z, Chen SS, Chandra PK, et al. Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol. 2009;22:1023-1031.